Article Cited by others

COMMENTARY

What failed BIA 10-2474 Phase I clinical trial? Global speculations and recommendations for future Phase I trials

Kaur Rimplejeet, Sidhu Preeti, Singh Surjit

Year : 2016| Volume: 7| Issue : 3 | Page no: 120-126

   This article has been cited by
 
1 Median Nerve Stimulation as a Nonpharmacological Approach to Bypass Analgesic Tolerance to Morphine: A Proof-of-Concept Study in Mice
Ming Tatt Lee, Yi-Hung Chen, Ken Mackie, Lih-Chu Chiou
The Journal of Pain. 2021; 22(3): 300
[Pubmed]  [Google Scholar] [DOI]
2 Analgesic drug development: proof-of-mechanism and proof-of-concept in early phase clinical studies
Hemme J. Hijma, Geert Jan Groeneveld
Medicine in Drug Discovery. 2021; 10: 100083
[Pubmed]  [Google Scholar] [DOI]
3 Modulatory role of the Endocannabinoidome in the pathophysiology of the gastrointestinal tract
Jerome Lian, Ilaria Casari, Marco Falasca
Pharmacological Research. 2021; : 106025
[Pubmed]  [Google Scholar] [DOI]
4 Organs-on-chips: into the next decade
Lucie A. Low, Christine Mummery, Brian R. Berridge, Christopher P. Austin, Danilo A. Tagle
Nature Reviews Drug Discovery. 2021; 20(5): 345
[Pubmed]  [Google Scholar] [DOI]
5 A NIR fluorescent probe for fatty acid amide hydrolase bioimaging and its application in development of inhibitors
Manman Tian, Zhenhao Tian, Dahong Yao, Jing Ning, Sa Deng, Lei Feng, Xiaokui Huo, Xiangge Tian, Baojing Zhang, Chao Wang, Zhenlong Yu, Xiaochi Ma
Journal of Materials Chemistry B. 2021; 9(32): 6460
[Pubmed]  [Google Scholar] [DOI]
6 The endocannabinoid system as a therapeutic target for schizophrenia: Failures and potentials
Alexandre Seillier
Neuroscience Letters. 2021; 759: 136064
[Pubmed]  [Google Scholar] [DOI]
7 Reviewing the Role of the Endocannabinoid System in the Pathophysiology of Depression
Ines Gallego-Landin, Alba García-Baos, Adriana Castro-Zavala, Olga Valverde
Frontiers in Pharmacology. 2021; 12
[Pubmed]  [Google Scholar] [DOI]
8 The Endocannabinoid System and Cannabidiol: Past, Present, and Prospective for Cardiovascular Diseases
Martina Rabino, Sara Mallia, Elisa Castiglioni, Davide Rovina, Giulio Pompilio, Aoife Gowran
Pharmaceuticals. 2021; 14(9): 936
[Pubmed]  [Google Scholar] [DOI]
9 Cannabinoid treatment of opiate addiction
Erin McLemon, Rose Chesworth
Neuroanatomy and Behaviour. 2021; 3: e14
[Pubmed]  [Google Scholar] [DOI]
10 Considerations for Cannabis Use to Treat Pain in Sickle Cell Disease
Donovan A. Argueta, Anupam Aich, Fjolla Muqolli, Hemanth Cherukury, Varun Sagi, Nicholas V. DiPatrizio, Kalpna Gupta
Journal of Clinical Medicine. 2020; 9(12): 3902
[Pubmed]  [Google Scholar] [DOI]
11 Effect of moderate activity on liver function and serum lipid level in healthy subjects during the phase I clinical trial
Hong Zhang, Ting Liu, Cuiyun Li, Xiaojiao Li, Yanhua Ding
Expert Opinion on Drug Metabolism & Toxicology. 2020; 16(12): 1217
[Pubmed]  [Google Scholar] [DOI]
12 Monitoring from Battlefield to Bedside: Serum Repositories Help Identify Biomarkers, Perspectives on Mild Traumatic Brain Injury
Mulugu V Brahmajothi, Mohamed B Abou-Donia
Military Medicine. 2020; 185(Supplement): 197
[Pubmed]  [Google Scholar] [DOI]
13 Human CNS barrier-forming organoids with cerebrospinal fluid production
Laura Pellegrini, Claudia Bonfio, Jessica Chadwick, Farida Begum, Mark Skehel, Madeline A. Lancaster
Science. 2020; 369(6500)
[Pubmed]  [Google Scholar] [DOI]
14 Toxicology Paradise: Sorting Out Adverse and Non-adverse Findings in Animal Toxicity Studies
Paul Baldrick, Mary Ellen Cosenza, Tessie Alapatt, Brad Bolon, Melissa Rhodes, Ian Waterson
International Journal of Toxicology. 2020; 39(5): 365
[Pubmed]  [Google Scholar] [DOI]
15 Advances in Multidimensional Cardiac Biosensing Technologies: From Electrophysiology to Mechanical Motion and Contractile Force
Xinwei Wei, Liujing Zhuang, Hongbo Li, Chuanjiang He, Hao Wan, Ning Hu, Ping Wang
Small. 2020; 16(50): 2005828
[Pubmed]  [Google Scholar] [DOI]
16 Novel Analgesics with Peripheral Targets
Cosmin I. Ciotu, Michael J. M. Fischer
Neurotherapeutics. 2020; 17(3): 784
[Pubmed]  [Google Scholar] [DOI]
17 Psychosocial and Biological Aspects of Synthetic and Natural FAAH Inhibitors
David A Dawson
Edelweiss Journal of Biomedical Research and Review. 2019; : 6
[Pubmed]  [Google Scholar] [DOI]
18 Characterization of fatty acid amide hydrolase activity by a fluorescence-based assay
Florian M. Dato,Andreas Maaßen,Bernd Goldfuß,Markus Pietsch
Analytical Biochemistry. 2018;
[Pubmed]  [Google Scholar] [DOI]
19 CRISPR Ethics: Moral Considerations for Applications of a Powerful Tool
Carolyn Brokowski,Mazhar Adli
Journal of Molecular Biology. 2018;
[Pubmed]  [Google Scholar] [DOI]
20 Enhanced endocannabinoid tone as a potential target of pharmacotherapy
Marek Toczek,Barbara Malinowska
Life Sciences. 2018; 204: 20
[Pubmed]  [Google Scholar] [DOI]
21 Drug conjugates-an emerging approach to treat breast cancer
Mahmud Hasan,Rehana K. Leak,Robert E. Stratford,Darius P. Zlotos,Paula A. Witt-Enderby
Pharmacology Research & Perspectives. 2018; 6(4): e00417
[Pubmed]  [Google Scholar] [DOI]
22 The cannabinoid system and pain
Stephen G. Woodhams,Victoria Chapman,David P. Finn,Andrea G. Hohmann,Volker Neugebauer
Neuropharmacology. 2017;
[Pubmed]  [Google Scholar] [DOI]
23 Contrasting effects of selective MAGL and FAAH inhibition on dopamine depletion and GDNF expression in a chronic MPTP mouse model of Parkinsonæs disease
Noemi Pasquarelli,Christoph Porazik,Hanna Bayer,Eva Buck,Stefan Schildknecht,Patrick Weydt,Anke Witting,Boris Ferger
Neurochemistry International. 2017;
[Pubmed]  [Google Scholar] [DOI]
24 Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?
Carina Hasenoehrl,Martin Storr,Rudolf Schicho
Expert Review of Gastroenterology & Hepatology. 2017; : 1
[Pubmed]  [Google Scholar] [DOI]

 

Read this article